The National Health Care Security Administration said negotiations on drugs covered by China’s national medical insurance system concluded on Sunday, with the inclusion of two new anti-COVID-19 drugs .
Three anti-COVID drugs, including Pfizer’s antiviral combination Paxlovid, Azvudine tablets and a granulated herbal medicine, were part of the negotiations, and the last two entered the list, an official said. administration.
Paxlovid was not included due to its high price, the official said, adding that under current policy, the medical insurance system would continue to reimburse the use of Paxlovid until the end of March. .
As a result of the negotiations, there are now more than 600 kinds of drugs to treat COVID-related symptoms, such as fever and cough, in the catalog of drugs covered by the national medical insurance system, said Noted the manager.
In the next step, the administration will further adjust the catalog to effectively reduce the burden on patients, he said, adding that the final results of the catalog negotiations are expected to be announced in the near future.
:quality(85)/cloudfront-us-east-1.images.arcpublishing.com/infobae/BWWJVUHTCJFRDLGGSKPXELPZH4.jpg?fit=%2C&ssl=1)
